Related to Australia Approves Biogen Idec’s Fampyra for Improving Walking Ability in Multiple Sclerosis

• Opinion—Regulatory Planning Key for Emerging Technology Companies
  Strategies formed early help keep investors and partners happy as well as create a smoother development path.
  
• Biogen Idec and Facet—Following the Money
  Facet considers Biogen’s $356 million takeover attempt a low-ball offer.
  
• Advancing Stem Cell Therapies for Multiple Sclerosis
  UKSCF partners with MS Society to financially support clinical development.
  
• Lupus Drug Development Remains Risky Business
  Research to understand underlying causes is, nonetheless, prompting some interest.
  
• Osiris’ Race to Market an FDA-Approved Stem Cell Product
  Mesenchymal stem cell therapy Prochymal is in Phase III but still has challenges to overcome.
  
• Changes Brewing at the FDA for Orphan Drugs
  Initiatives to de-risk drug development could include redesigning clinical trial requirements.
  
• 2010 in Review: Biotechnology Highlights
  Gene patenting and ESCs were back in the headlines along with breakthroughs in sequencing, syn bio, and other fields.
  
• Reporting from J.P. Morgan on Drug Development Companies
  Even the unseasonal cold couldn’t dampen the spirit of the biotech community.